Cargando…
Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients
PURPOSE: To characterize current experiences with communication and decision-making practices when non-medical switching to a biosimilar trastuzumab is proposed or required by cancer center or insurer. METHODS: We developed and launched 60- and 51-item internet surveys to elicit US breast cancer pat...
Autores principales: | Papautsky, Elizabeth Lerner, Carlson, Martha, Johnson, Sheila M., Montague, Hannah, Attai, Deanna J., Lustberg, Maryam B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107314/ https://www.ncbi.nlm.nih.gov/pubmed/35568748 http://dx.doi.org/10.1007/s10549-022-06615-2 |
Ejemplares similares
-
Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)
por: Yao, Katharine A., et al.
Publicado: (2021) -
Biosimilars 101: considerations for U.S. oncologists in clinical practice
por: Camacho, Luis H, et al.
Publicado: (2014) -
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
por: Lewis Phillips, Gail, et al.
Publicado: (2021) -
Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021) -
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)